GSK Looks 15.2% Overvalued on GF Value™ Amid Solid Dividend Fund
On August 24, 2026, GSK PLC (NYSE: GSK) announced that the FDA has accepted its supplemental Biologics License…
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the global pharmaceutical and oncology company, traded at $164.75 Thursday…
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Suc
AstraZeneca AZN, the global pharmaceutical and oncology company, traded at $164.75 Thursday as positive Tezspire data failed to…
ANF Maintains by Barclays — Price Target Raised to $155
On October 18, 2023, Barclays maintained its Equal-Weight rating for Abercrombie & Fitch (ANF) while significantly raising the…
BBWI Maintained by Barclays — Price Target Lowered to $22
On August 27, 2026, Barclays maintained an Equal-Weight rating on Bath & Body Works BBWI while lowering the…
GSK Looks 15.2% Overvalued on GF Value™ as Dividend Sustainabili
On August 24, 2026, GSK PLC (NYSE: GSK) announced that the FDA has accepted for priority review its…
HSBC Plans Restructuring in Singapore to Streamline Operations
On August 26, 2026, HSBC Holdings PLC (NYSE: HSBC) announced a significant reorganization of its operations in Singapore,…
GSK Looks 15.2% Overvalued on GF Value™ as Dividend Sustainabili
On August 24, 2026, GSK (NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare approved Hibsago,…
GSK Looks 13.2% Overvalued on GF Value™ as Dividend Sustainabili
On August 26, 2026, new research published in Nature Medicine highlighted that GSK PLC’s (NYSE: GSK) shingles vaccine,…
NCNO Maintained by Barclays — Price Target Raised to $23
On August 26, 2026, Barclays maintained an Overweight rating for Ncino NCNO, raising the price target from $22.00…
DKS Maintained by Barclays — Price Target Lowered to $150
On October 23, 2023, Barclays maintained an Overweight rating on Dick’s Sporting Goods DKS. The price target has…
CPRT Maintains Underweight Rating by Barclays — Price Target Lo
On October 23, 2023, Barclays maintained its Underweight rating on Copart (CPRT) while lowering the price target from…